Persistence Pays Off for Tacere Execs
This article was originally published in Start Up
Executive Summary
RNAi firm Tacere's deal with Pfizer demonstrates pharmaceutical companies' interest in exploring a variety of RNA interference techniques as well as the rewards sometimes associated with the dogged development of a single project.